Sensei Biotherapeutics, Inc. financial data

Symbol
SNSE on Nasdaq
Industry
Pharmaceutical Preparations
Location
1405 Research Blvd, Suite 125, Rockville, MD
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17K % -12.2%
Debt-to-equity 14.6 % +7.2%
Return On Equity -48.1 % -4.2%
Return On Assets -42 % -3.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.2M shares -5.39%
Common Stock, Shares, Outstanding 25.1M shares -5.49%
Entity Public Float 18.7M USD -48.6%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 25.1M shares -17.7%
Weighted Average Number of Shares Outstanding, Diluted 25.1M shares -17.7%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 14.6M USD -32.6%
Operating Income (Loss) -32.4M USD +32.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -29.7M USD +34.4%
Earnings Per Share, Basic -1.18 USD/shares +20.3%
Earnings Per Share, Diluted -1.18 USD/shares +20.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.9M USD +16.3%
Other Assets, Current 142K USD -43.7%
Assets, Current 53.9M USD -33.5%
Property, Plant and Equipment, Net 1.04M USD -29.3%
Operating Lease, Right-of-Use Asset 3.57M USD -28.8%
Other Assets, Noncurrent 87K USD +1.16%
Assets 59.8M USD -33.2%
Employee-related Liabilities, Current 848K USD +18.6%
Liabilities, Current 4.95M USD -7.62%
Operating Lease, Liability, Noncurrent 2.21M USD -41.6%
Other Liabilities, Noncurrent 67K USD -6.94%
Liabilities 7.61M USD -26.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -93K USD +83.1%
Retained Earnings (Accumulated Deficit) -247M USD -13.7%
Stockholders' Equity Attributable to Parent 52.2M USD -34.1%
Liabilities and Equity 59.8M USD -33.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.62M USD +35.1%
Net Cash Provided by (Used in) Financing Activities -209K USD +20.2%
Net Cash Provided by (Used in) Investing Activities 5.77M USD +150%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 25.1M shares -5.49%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.06M USD +78.8%
Deferred Tax Assets, Valuation Allowance 51.1M USD +23.4%
Deferred Tax Assets, Gross 52.7M USD +23.3%
Operating Lease, Liability 3.81M USD -27.2%
Payments to Acquire Property, Plant, and Equipment 37K USD -75.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -29.2M USD +34.4%
Lessee, Operating Lease, Liability, to be Paid 4.14M USD -29.9%
Property, Plant and Equipment, Gross 3.04M USD +0.07%
Operating Lease, Liability, Current 1.59M USD +10.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.41M USD -18.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.74M USD -4.72%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 333K USD -50.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 59K USD -95.8%
Deferred Tax Assets, Operating Loss Carryforwards 33.3M USD +22.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 59K USD -95.8%
Operating Lease, Payments 462K USD +12.7%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 1.61M USD 0%
Depreciation, Depletion and Amortization 544K USD -11.1%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 1.59M USD 0%
Deferred Tax Assets, Net of Valuation Allowance 1.63M USD +18.2%
Share-based Payment Arrangement, Expense 4.16M USD -20.2%
Operating Leases, Future Minimum Payments, Due in Three Years 1.64M USD 0%
Operating Leases, Future Minimum Payments Due 7.99M USD 0%
Interest Expense 116K USD -36.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%